ASN Kidney Week - American Society of Nephrology Kidney Week

It may be worth considering the pathophysiology and vascular complications of chemotherapy, especially among patients who are already hypertensive.

Pharmacy Times will be covering the American Society of Nephrology (ASN) Kidney Week, which will be gathering more than 10,000 professionals working on kidney health in Orlando, Florida.

Pharmacy Times is gearing up for Kidney Week (Nov. 3-6) by learning about the pharmacological role of kidney care from the president of the American Society of Nephrology.

Peter Stenvinkel, MD, PhD, FASN, full professor and senior lecturer at Karolinska University Hospital, Karolinska Institutet, discusses the role of Nrf2 and vitamin K in DNA damage signaling, senescence, and inflammaging.

Peter Stenvinkel, MD, PhD, FASN, full professor and senior lecturer at Karolinska University Hospital, Karolinska Institutet, discusses the link between senescence and early vascular aging in the context of chronic kidney disease.

Peter Stenvinkel, MD, PhD, FASN, full professor and senior lecturer at Karolinska University Hospital, Karolinska Institutet, discusses what may be some of the contributing factors to early vascular aging and how might they be counteracted.

Peter Stenvinkel, MD, PhD, FASN, full professor and senior lecturer at Karolinska University Hospital, Karolinska Institutet, discusses the next steps to identify and develop novel and effective therapeutic targets for vascular calcification and early vascular aging.

Peter Stenvinkel, MD, PhD, FASN, full professor and senior lecturer at Karolinska University Hospital, Karolinska Institutet, discusses the therapeutic strategies or treatments for vascular calcification that have been found to be effective in patients with chronic kidney disease.

Peter Stenvinkel, MD, PhD, FASN, full professor and senior lecturer at Karolinska University Hospital, Karolinska Institutet, discusses what the current clinical therapeutic strategies and novel treatments are for vascular calcification.

Paolo Raggi, MD, PhD, professor at the department of medicine in the division of cardiology at the University of Alberta, discusses the cardiovascular effects of chronic kidney disease.

Peter Stenvinkel, MD, PhD, FASN, full professor and senior lecturer at Karolinska University Hospital, Karolinska Institutet, discusses how medial vascular calcification impacts early vascular aging.

Paolo Raggi, MD, PhD, professor at the department of medicine in the division of cardiology at the University of Alberta, discusses how pharmacists are limited to traditional treatment of chronic kidney disease, while waiting for new treatment options.

Peter Stenvinkel, MD, PhD, FASN, full professor and senior lecturer at Karolinska University Hospital, Karolinska Institutet, discusses what early vascular aging is, and what its implications are when it occurs in patients with chronic kidney disease.

Paolo Raggi, MD, PhD, professor at the department of medicine in the division of cardiology at the University of Alberta, discusses promising new crystallization treatment of vascular calcification.

Paolo Raggi, MD, PhD, professor at the department of medicine in the division of cardiology at the University of Alberta, discusses the effects of vascular calcifications if not successfully prevented.

Paolo Raggi, MD, PhD, professor at the department of medicine in the division of cardiology at the University of Alberta, discusses the role pharmacists play in helping individuals with vascular calcification and chronic kidney disease.

Boyd hopes to see the various study results on diet's role in conditions such as high blood pressure and chronic kidney disease to further help patients.

Paolo Raggi, MD, PhD, professor at the department of medicine in the division of cardiology at the University of Alberta, discusses what the treatment options are to treat vascular calcification.

Dr. Cary Boyd-Shiwarski explained the effectiveness of potassium-binding agents in treating hyperkalemia in resistant hypertension and CKD.

Peter Stenvinkel, MD, PhD, FASN, full professor and senior lecturer at Karolinska University Hospital, Karolinska Institutet, discusses his presentation at the American Society of Nephrology’s Kidney Week 2021 on vascular aging in chronic kidney disease.

Paolo Raggi, MD, PhD, professor at the department of medicine in the division of cardiology at the University of Alberta, discusses how chronic kidney disease elevated the risk of vascular calcification and what the risks of vascular calcification are.

Dr. Cary Boyd-Shiwarski explains how nonsteroidal mineralcorticoid receptor antagonists and novel potassium-binding agents alter the management of hyperkalemia and approaching potassium handling in chronic kidney disease.

Boyd gave a general overview of how potassium handling works in chronic kidney disease, specifically with hyperkalemia.

Farzana Perwad, MD, chief of the Division of Nephrology at UCSF Benioff Children's Hospitals, discusses the common health impacts of phosphate metabolism disorders.

Farzana Perwad, MD, chief of the Division of Nephrology at UCSF Benioff Children's Hospitals, discusses the relationship between chronic kidney disease and disorders of phosphate metabolism.

Despoina Manousaki, MD, PhD, pediatric endocrinologist and assistant professor at CHU Sainte-Justine Research Centre, discusses the impact of uremia on vitamin D metabolism.

Despoina Manousaki, MD, PhD, pediatric endocrinologist and assistant professor at CHU Sainte-Justine Research Centre, discusses the relationship between uremia and chronic kidney disease.

Jun Ling Lu, MD, assistant professor, University of Tennessee Health Science Center, addresses next steps in research investigating the benefits of aspirin in patients with chronic kidney disease.

Chi Chu, MD, an assistant professor in the division of nephrology at the University of California San Francisco, why submaximal dosing is important in minimizing proteinuria and chronic kidney disease.

Jun Ling Lu, MD, assistant professor, University of Tennessee Health Science Center, addresses the implications of study results assessing long-term aspirin use and the progression of kidney disease.